9月22日 - ** 制药商Ionis Pharmaceuticals IONS.O 股价盘前上涨2.3%至62.4美元
** IONS称其实验性药物zilganersen改善了一种罕见的渐进性、通常致命的神经系统疾病患者的 (link) 步行能力，达到了早期至晚期研究的主要目标。
** 在对54名患者进行的研究中，接受50毫克剂量zilganersen治疗的患者在61周时通过10米步行测试（一种功能活动能力评估方法）对步态速度的评估显示出统计学意义上的显著改善
** 这种试验性药物正在开发中，用于治疗亚历山大病，这种疾病会损害脑细胞，导致运动、语言和吞咽困难，通常从幼儿期就开始出现。
** 截至上一交易日收盘，IONS股价年累计上涨74.5%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.